| 2026-08-17 | Press release | Castle Biosciences Approved for Dual Listing on Nasdaq Texas |
| 2026-07-30 | Press release | Castle Biosciences Reports Second Quarter 2026 Results |
| 2026-07-22 | Press release | Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference |
| 2026-07-14 | Press release | Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test |
| 2026-07-09 | Press release | Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 |
| 2026-06-25 | Press release | DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Nod |
| 2026-06-23 | Press release | Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal |
| 2026-06-19 | Press release | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-16 | Press release | Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with B |
| 2026-05-13 | Press release | Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-12 | Press release | Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation |
| Press release | Castle Biosciences Reports First Quarter 2026 Results |
| 2026-05-06 | Presentation | PresentationPDF |
| 2026-05-27 | Press release | https://www.prnewswire.com/news-releases/castle-biosciences-reports-first-quarter-2026-results-302763284.html |
| 2026-05-26 | Press release | https://www.prnewswire.com/news-releases/castle-biosciences-reports-first-quarter-2026-results-302763284.html |
| 2026-05-05 | Fact sheet | Quarterly FactsheetPDF |
| 2026-05-04 | Press release | New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barre |
| 2026-05-06 | Press release | Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 |
| 2026-04-01 | Annual report | View Featured Report |
| 2026-03-27 | Press release | Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Perso |
| 2026-03-04 | Press release | Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients |
| Press release | Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results |
| 2026-02-26 | Presentation | Corporate Presentation |
| Press release | Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely |
| 2026-02-26 | Press release | Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, |
| Press release | Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results |
| 2026-01-09 | Earnings deck | Castle Preliminary Fourth Quarter and Full-Year 2025 Results Slide Presentation |
| Press release | Castle Biosciences Reports Third Quarter 2025 Results |
| 2025-11-03 | Presentation | AdvancedAD-Tx PresentationPDF |
| 2025-11-01 | Presentation | Corporate Presentation |
| 2025-10-31 | Fact sheet | Quarterly FactsheetPDF |
| Press release | Castle Biosciences Reports Second Quarter 2025 Results |
| 2025-08-04 | Presentation | Corporate Presentation |
| 2025-08-01 | Fact sheet | Quarterly FactsheetPDF |
| Press release | Castle Biosciences to Acquire Previse |
| Press release | Castle Biosciences Reports First Quarter 2025 Results |
| 2025-05-05 | Presentation | Corporate Presentation |
| 2025-05-05 | Earnings deck | PresentationPDF |
| 2025-04-20 | Fact sheet | Quarterly FactsheetPDF |
| Press release | Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships |